Bruce Clurman, MD, PhD
In his 25th year as a physician and researcher working at Fred Hutchinson Cancer Research Center, Bruce Clurman, MD, PhD, recently stepped into his newest role—Executive Vice President and Deputy Director of Fred Hutch. Fred Hutch President and Director Gary Gilliland, MD, PhD, recently announced Dr. Clurman’s appointment, which became effective November 1.
Dr. Clurman takes over the position from outgoing Executive Vice President and Deputy Director Mark Groudine, MD, PhD, who served in those roles for 11 and 19 years, respectively. Dr. Groudine will continue to lead his basic research laboratory and will serve as Special Advisor to the Director’s Office. Dr. Clurman will work alongside Fred Hutch’s other Executive Vice President and Deputy Director, Fred Appelbaum, MD, who has held that position since 2013. Dr. Clurman will also serve on the board of Seattle Cancer Care Alliance (SCCA), Fred Hutch’s clinical care partner.
Mark Groudine, MD, PhD
Fred Appelbaum, MD
Logical Transition
Dr. Clurman has been instrumental in orchestrating Fred Hutch’s recently completed 5-year strategic plan, Dr. Gilliland said. He has also led the coordination and planning for Fred Hutch’s Integrated Research Centers, new research groups underway that will unite scientists and clinicians from diverse focus areas to attack major problems facing cancer and other diseases.
For Dr. Clurman, the transition seems a logical next step in a career built at Fred Hutch, working across disciplines as both a transplantation physician, seeing patients with blood cancers at SCCA, and as a basic scientist. Dr. Clurman joined Fred Hutch in 1991 as a Senior Fellow in Oncology working in Dr. Groudine’s lab. ■
